20S Proteasome News

News

High Rate of CR Shown With Monoclonal Antibody REGN5458 for Heavily Pretreated R/R MM

03/03/2022

Nearly half of patients had a complete response with REGN5458, a BCMA-CD3 bispecific antibody monotherapy to treat heavily pretreated R/R MM.

Nearly half of patients had a...

03/03/2022

Oncology

News

Isatuximab Plus Pomalidomide and Dexamethasone: New Standard of Care for Relapsed/Refractory MM

03/02/2022

John Otrompke , BA, JD;

A novel combination of isatuximab plus standard of care pomalidomide and dexamethasone resulted in improved OS for patients with R/R MM, according to the phase 3 ICARIA-MM trial.

A novel combination of...

03/02/2022

Oncology

News

FDA Approves BCMA-Directed CAR-T Immunotherapy for R/R MM

03/01/2022

The FDA has approved ciltacabtagene autoleucel, a novel CAR-T immunotherapy regimen to target BCMA in patients with R/R MM.

The FDA has approved...

03/01/2022

Oncology

News

Phase 3 CANDOR Trial Confirms Triplet Regimen Improves PFS for R/R MM

02/09/2022

Final analysis results of the phase 3 CANDOR study confirm improved PFS and longer follow-up outcomes of carfilzomib, daratumumab, and dexamethasone for patients with R/R MM.

Final analysis results of the...

02/09/2022

Oncology

News

Ixazomib Combo With Pomalidomide, Dexamethasone Increases PFS in Patients With R/R MM

01/28/2022

Results from a phase 1/2 study showed adding ixazomib to pomalidomide and dexamethasone as part of a second line therapy increased PFS in patients with R/R MM and warrants future phase III investigations.

Results from a phase 1/2 study...

01/28/2022

Oncology

News

Triplet Combo Therapy Provides Limited Toxicity in Relapsed MM

12/02/2021

Phase 2 data were presented at the 2021 ASH Annual Meeting for a subgroup of relapsed patients with MM who had durable responses to ixazomib, lenalidomide, and dexamethasone.

Phase 2 data were presented at...

12/02/2021

Oncology

News

20S Proteasome and UCH-L1 Concentrations Investigated as Biomarkers in TCC

10/04/2021

SPRi-based biosensors were used to analyze 20S proteasome and UCH-L1 concentrations in bodily fluids of patients with TCC to understand the relationship between ubiquitin and proteasome and cancer progression.

SPRi-based biosensors were used...

10/04/2021

Oncology

News

FDA Approves Melphalan Flufenamide for Relapsed/Refractory MM

03/03/2021

The FDA has approved melphalan flufenamide plus dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (MM).

The FDA has approved melphalan...

03/03/2021

Oncology

News

FDA Approves New CAR-T Therapy for R/R Large B-Cell Lymphoma

02/19/2021

The FDA has approved lisocabtagene maraleucel, a new CAR-T therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after at least 2 lines of systemic therapy.

The FDA has approved...

02/19/2021

Oncology

News

Experts Show Potential of miR-100 Against MCL Cell Proliferation

10/06/2020

Findings from a clinical study suggest that miR-100 may be an anti-MCL gene.

Findings from a clinical study...

10/06/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology